In June 2019, Biorek S.r.l. launched, as sponsor, an European, prospective, multicenter and observational Clinical Study (Biomarkers of Renal Cancer, BRC:
ClinicalTrials.gov n° NCT05785052), with the enrollment of 1,000 patients (cases and controls), concluded in March 2023.

The study also provides for a 36-month post-surgical follow-up for each enrolled patient and will therefore be completed in 2026.

During the study, pre-operative biological samples (whole blood, plasma, and urine) were collected according to a standardized laboratory protocol applied across all the
enrolling centers and were stored in a certified biobank, which currently holds about 20,000 aliquots.